Overview

A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.

Status:
Completed

Trial end date:
2019-05-06

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine the comparability of the safety and efficacy of Mupirocin Calcium Cream, 2% and Bactroban® Cream in subjects with secondarily infected traumatic skin lesions. It will also be determined whether the efficacy of each of the active treatments is superior to that of the vehicle cream (placebo).

Phase:

Phase 1

Details

Lead Sponsor:

Taro Pharmaceuticals USA

Treatments:

Calcium
Calcium, Dietary
Mupirocin